Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A securities class action has been filed against Aardvark Therapeutics over alleged misstatements and omissions related to the safety and clinical, regulatory, and commercial prospects of ARD-101. The suit covers investors who bought shares in Aardvark's February 13, 2025 IPO or between February 13, 2025 and May 14, 2026; investors have until October 13, 2026 to seek lead-plaintiff status. The allegations create legal and reputational risk for Aardvark and could pressure its shares, though no liability or damages have been established.

Analysis

This is primarily a liquidity and governance overhang rather than a new fundamental data point. Plaintiff-law-firm notices are commonly follow-on events and, absent a new regulatory filing, trial update, FDA correspondence, or disclosed safety signal, should not independently alter probability-weighted valuation. The near-term effect is likely wider bid-ask spreads and reduced marginal demand from event-driven and long-only healthcare holders, particularly if AARD has limited float; D&O insurance should limit direct cash exposure at this stage, but management distraction can matter disproportionately for a clinical-stage issuer.

The material question is whether the complaint uncovers safety information that was previously nonpublic, rather than whether litigation proceeds. Over the next 1-3 months, any amendment to the complaint, SEC response, insider-sale disclosure, protocol change, enrollment pause, or revised ARD-101 safety presentation would create a more durable multiple and probability-of-success reset. Conversely, no corroborating clinical or regulatory disclosure by the October 13 lead-plaintiff deadline would support the view that the headline-driven selloff is overextended; litigation itself can persist for years without determining the asset's commercial value.

Key Decisions for Investors

• Do not initiate a directional AARD short solely on this notice; borrow availability and a small-cap biotech's clinical-news gap risk can make the downside-to-squeeze asymmetry unattractive over days to weeks.
• Place AARD on a 1-3 month negative-catalyst watchlist: reassess for a short only if management discloses a serious adverse event, trial modification, enrollment disruption, or lowered regulatory guidance. A confirmed change to the ARD-101 safety profile would be the thesis trigger, not the lawsuit filing.
• For existing AARD longs, reduce position size to binary-event limits and avoid adding until the next independently verifiable clinical/regulatory update clarifies whether safety risk changes the program's probability of approval.
• If the stock declines materially with no corroborating disclosure, evaluate a tactical rebound position only after confirming stable cash runway, no FDA hold or protocol amendment, and normal trial enrollment; invalidate the rebound thesis on any formal safety-related regulatory action or guidance withdrawal.